Kane Biotech Inc. (TSXV:KNE)
Canada · Delayed Price · Currency is CAD 0.0300
0.00 (0.00%)
Jun 10, 2026, 3:44 PM EST
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.06 | 0.43 | 2.08 | 0.15 | 2.67 | 1.61 | |
Revenue Growth (YoY) | -97.60% | -79.44% | 1296.75% | -94.42% | 65.96% | 19.84% |
Cost of Revenue | 0.11 | 0.43 | 1.21 | - | 1.26 | 1.04 |
Gross Profit | -0.05 | -0 | 0.87 | 0.11 | 1.41 | 0.57 |
Selling, General & Admin | 1.5 | 1.98 | 3.08 | 2.41 | 3.72 | 4.07 |
Research & Development | 0.62 | 0.67 | 1.72 | 1.05 | 1.05 | 1.38 |
Total Operating Expenses | 2.12 | 2.65 | 4.8 | 3.47 | 4.78 | 5.45 |
Operating Income | -0.67 | -2.65 | -3.92 | -3.36 | -3.36 | -4.88 |
Interest Income | -0.02 | -0.02 | -0 | - | 0.92 | 0.54 |
Interest Expense | 0.24 | 0.24 | 0.55 | - | - | - |
Other Non-Operating Income (Expense) | 0.18 | 0.17 | 0.54 | - | -0.21 | 0.35 |
Total Non-Operating Income (Expense) | 0.4 | 0.39 | 1.08 | - | 0.71 | 0.89 |
Pretax Income | -0.27 | -2.26 | -2.84 | -3.36 | -2.65 | -3.99 |
Provision for Income Taxes | 0 | -0.11 | -1.31 | - | - | - |
Net Income | -0.28 | -2.72 | -3.16 | -3.36 | -2.65 | -3.99 |
Minority Interest in Earnings | - | - | 0.07 | - | 0.07 | -0.25 |
Earnings From Discontinued Operations | - | - | 18.59 | -0.71 | - | - |
Net Income to Common | -2.22 | -2.72 | 6.17 | -5.27 | -3.82 | -4.85 |
Shares Outstanding (Basic) | 222 | 162 | 134 | 127 | 121 | 113 |
Shares Outstanding (Diluted) | 222 | 162 | 155 | 127 | 121 | 113 |
Shares Change (YoY) | 39.02% | 4.40% | 22.23% | 5.32% | 7.20% | 3.67% |
EPS (Basic) | -0.01 | -0.02 | -0.02 | -0.04 | -0.03 | -0.04 |
EPS (Diluted) | -0.01 | -0.02 | -0.02 | -0.04 | -0.03 | -0.04 |
Free Cash Flow | -2.63 | -3.26 | -4.14 | -2.09 | -3.05 | -2.48 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 |
Gross Margin | -80.22% | -0.15% | 41.91% | 73.48% | 52.96% | 35.36% |
Operating Margin | -1149.49% | -620.25% | -188.53% | -2253.58% | -126.06% | -303.75% |
Profit Margin | -471.92% | -636.00% | -151.91% | -2253.58% | -99.44% | -248.30% |
FCF Margin | -4487.53% | -761.99% | -198.77% | -1403.79% | -114.40% | -153.99% |
EBITDA | -0.54 | -2.49 | -3.7 | -3.12 | -3.11 | -4.7 |
EBITDA Margin | -920.91% | -582.21% | -178.03% | -2093.43% | -116.41% | -292.06% |
EBIT | -0.67 | -2.65 | -3.92 | -3.36 | -3.36 | -4.88 |
EBIT Margin | -1149.49% | -620.25% | -188.53% | -2253.58% | -126.06% | -303.75% |
Effective Tax Rate | -1.55% | 4.78% | 46.10% | 0.00% | 0.00% | 0.00% |